A Phase 2 interventional study of Cetuximab and FOLFOX induction regimen in Colorectal Cancer, sponsored by Hoffmann-La Roche. Completed at 154 sites in 23 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-06.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 187 studies testing cetuximab in Colorectal Neoplasms — 35 open to participants now, 43 under way, 7 of them phase 3. Cetuximab · Colorectal Neoplasms.
Among the 187 studies testing cetuximab in Colorectal Neoplasms, this one is the 9th largest by enrollment of the 185 interventional ones that give a count, is one of 5 that started in 2015, is one of 107 in phase 2, and was the 108th registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →35 of the 187 studies testing cetuximab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Haisco Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18+
Verastem, Inc. · Sites in United States, Australia
Ages 18+
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
187 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 39 · Phase 2 131 · Phase 3 33 · Phase 4 4
First in 1999; this study’s year is marked. 5 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,044 is above the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 60 across the 185 interventional studies. Of the 108 that completed or were terminated, 29 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 187 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
111 studies in Colorectal Neoplasms by Hoffmann-La Roche: 3 open now, 7 under way, none of them phase 3. Of 99 finished, 52 (53%) have results posted.
Among the 111 studies in Colorectal Neoplasms by Hoffmann-La Roche, this one is the 5th largest by enrollment of the 77 interventional ones that give a count, is one of 5 that started in 2015, is one of 32 in phase 2, and was the 82nd registered.
Hoffmann-La Roche’s Colorectal Neoplasms studies by the year they started, since 1998.
6 of the studies testing cetuximab in Colorectal Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06226857Phase 3City Clinical Oncology Hospital No 1Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer | 2026-12-31 |
| NCT06321081Beijing HospitalICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC | 2026-12-30 |
| NCT05706779Federation Francophone de Cancerologie DigestiveEncorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer | 2026-12-30 |
| NCT06411600Vall d'Hebron Institute of OncologyCombination Therapy for BRAF-V600E Metastatic CRCm | 2027-05-01 |
| NCT07659795Verastem, Inc.A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer | 2027-06 |
Add all 6 to your calendar (.ics) → With an account.
Among the 187 studies testing cetuximab in Colorectal Neoplasms, from their registry updates:
Among Hoffmann-La Roche’s 111 in Colorectal Neoplasms:
This tab as a report to print or save as PDF → With an account.
This randomized, multi-center, active-controlled, open-label, parallel-group study will investigate the efficacy and safety of biomarker-driven maintenance treatment for first-line mCRC. Participants with mCRC are eligible for entry and cannot have received any prior chemotherapy in the metastatic setting. The entire study duration is anticipated to be approximately 7.5 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria for All Participants:
Exclusion Criteria for Participants in Cohort 1 (MP):
Exclusion Criteria for Participants in Cohort 2 (MP):
Exclusion Criteria for Participants in Cohort 3 (MP):
Exclusion Criteria for Participants in Cohort 4 (MP):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Includes participants with v-raf murine sarcoma viral oncogene homolog B1 mutation positive (BRAFmut)/human epidermal growth factor receptor 2 negative (HER2-)/microsatellite stable (MSS)/rat sarcoma wild type (RASwt). All participants will receive either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab.
Drug: FOLFOX induction regimen · Drug: Bevacizumab · Drug: 5-FU/LV
Includes participants with BRAFwt. All participants will receive either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab.
Drug: FOLFOX induction regimen · Drug: Bevacizumab · Drug: 5-FU/LV
Includes participants with human epidermal growth factor receptor 2 positive (HER2+). All participants will receive either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab.
Drug: FOLFOX induction regimen · Drug: Bevacizumab · Drug: 5-FU/LV
Includes participants with HER2-/high microsatellite instability (MSI-H); HER2-/MSS/v-raf murine sarcoma viral oncogene homolog B1 wild type (BRAFwt); HER2-/MSS/BRAFmut/rat sarcoma mutation positive (RASmut). All participants will receive either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab.
Drug: FOLFOX induction regimen · Drug: Bevacizumab · Drug: 5-FU/LV
Participants with v-raf murine sarcoma viral oncogene homolog B1 mutation positive (BRAFmut)/human epidermal growth factor receptor 2 negative (HER2-)/microsatellite stable (MSS)/rat sarcoma wild type (RASwt) will receive 1600-2400 milligrams per square meter (mg/m\^2) 5-FU via 46-hour intravenous (IV) infusion in combination with 400 mg/m\^2 LV via 2-hour infusion on Day 1 of every 2-week cycle with 500 mg/m\^2 cetuximab via infusion on Day 1 of every 2-week cycle and 960 milligrams (mg) vemurafenib twice daily (BID) by mouth.
Drug: Cetuximab · Drug: Vemurafenib · Drug: 5-FU/LV
Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.
Drug: Fluoropyrimidine (5-FU/LV or capecitabine) · Drug: Bevacizumab
Participants with BRAFwt will receive fluoropyrimidine (1600-2400 mg/m\^2 5-FU via 46-hour IV infusion in combination with 400 mg/m\^2 LV via 2-hour infusion on Day 1 of every 2-week cycle or 1000 mg/m\^2 twice-daily capecitabine BID by mouth on Days 1-14 every 2 weeks followed by a 1-week break) with 5 milligrams per kilogram (mg/kg) bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle and 800 mg atezolizumab via 60-minute IV infusion on Day 1 of every 2-week cycle.
Drug: Fluoropyrimidine (5-FU/LV or capecitabine) · Drug: Atezolizumab · Drug: Bevacizumab
Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.
Drug: Fluoropyrimidine (5-FU/LV or capecitabine) · Drug: Bevacizumab
Participants with human epidermal growth factor receptor 2 positive (HER2+) will receive 1000 mg/m\^2 twice-daily capecitabine BID by mouth on Days 1-14 every 2 weeks followed by a 1-week break with trastuzumab by IV infusion on Day 1 of every 3-week treatment cycle at an initial loading dose of 8 mg/kg followed by 6 mg/kg for subsequent doses, and pertuzumab by IV infusion on Day 1 of each 3-week treatment cycle at an initial fixed loading dose of 840 mg followed by 420 mg for subsequent doses.
Drug: Trastuzumab · Drug: Pertuzumab · Drug: Capecitabine
Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.
Drug: Fluoropyrimidine (5-FU/LV or capecitabine) · Drug: Bevacizumab
Participants with HER2-/high microsatellite instability (MSI-H); HER2-/MSS/v-raf murine sarcoma viral oncogene homolog B1 wild type (BRAFwt); HER2-/MSS/BRAFmut/rat sarcoma mutation positive (RASmut) will receive 60 mg cobimetinib orally for 3 weeks followed by a 1-week treatment break and atezolizumab at a fixed dose of 840 mg via 60-minute IV infusion on Day 1 of every 2-week cycle.
Drug: Atezolizumab · Drug: Cobimetinib
Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.
Drug: Fluoropyrimidine (5-FU/LV or capecitabine) · Drug: Bevacizumab
BRAFmut participants experiencing early disease progression during induction treatment will have the option of proceeding immediately to receive second-line treatment with 5-FU/LV, cetuximab and vemurafenib if their primary tumor is MSS, or with a fluoropyrimidine (5-FU/LV or capecitabine), bevacizumab, and atezolizumab if their primary tumor is MSI-H. This cohort will be followed for adverse events during the study, but is not part of the Maintenance Phase study objectives.
Drug: Cetuximab · Drug: Fluoropyrimidine (5-FU/LV or capecitabine) · Drug: Atezolizumab · Drug: Vemurafenib · Drug: Bevacizumab · Drug: 5-FU/LV
500 mg/m\^2 via IV infusion on Day 1 of every 2-week cycle
Administered per the Investigator's discretion in accordance with locally approved prescribing information.
Drug page: Fluoropyrimidine
Per Investigator's discretion: 5-FU 1600-2400 mg/m\^2 administered via 46-hour IV infusion on Day 1 of every 2-week cycle and LV 400 mg/m\^2 administered via a 2-hour infusion on Day 1 every 2 weeks or 1000 mg/m\^2 twice-daily capecitabine (BID) by mouth given days 1-14 every 2 weeks. The chosen fluoropyrimidine should be administered in accordance with local prescribing information.
800 mg atezolizumab via 60-minute IV infusion on Day 1 of every 2-week cycle, or a fixed dose of 840 mg
Also known as: MPDL3280A, RO5541267
960 mg vermurafenib BID by mouth
Also known as: RO5185426
5 mg/kg bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle per local prescribing information
Also known as: RO4876646
Initial loading dose of 8 mg/kg followed by 6 mg/kg for subsequent doses by IV infusion on Day 1 of every 3-week treatment cycle
Also known as: RO0452317
Initial fixed loading dose of 840 mg followed by 420 mg for subsequent doses by IV infusion on Day 1 of each 3-week treatment cycle
Also known as: RO4368451
60 mg orally once daily for 3 weeks followed by a 1-week treatment break
Also known as: RO5514041
1600-2400 mg/m\^2 5-FU via 46-hour IV infusion in combination with 400 mg/m\^2 LV via 2-hour infusion on Day 1 of every 2-week cycle until disease progression per the Investigator's assessment using modified Response Evaluation Criteria in Solid Tumors or death from any cause, whichever occurs first. The fluoropyrimidine should be administered in accordance with local prescribing information.
1000 mg/m\^2 twice-daily capecitabine (BID) by mouth given days 1-14 every 2 weeks. The fluoropyrimidine should be administered in accordance with local prescribing information.
Progression-Free Survival (PFS)
PFS is defined as the time from randomization to the first occurrence of disease progression according to RECIST v1.1, or death from any cause, whichever occurs first. Progressive disease (PD) for target lesion: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of \>/=5 mm. PD for non-target lesion: Unequivocal progression of existing non-target lesions.
Time frame: From randomization until disease progression or death from any cause, up to 5 years
Overall Survival (OS)
OS is defined as the time from randomization into the MTP to time of death from any cause.
Time frame: From randomization until death from any cause, up to 5 years
Percentage of Participants With Adverse Events
Time frame: From baseline until end of study (up to 5 years)
Overall Response
Calculated as the number of participants with a best overall response of CR or PR according to RECIST 1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. OR= CR + PR.
Time frame: From randomization until disease progression, up to 5 years
Disease Control Rate (DCR)
DCR is defined as the percentage of participants with CR, PR, or stable disease (SD) at 16 weeks. Per RECIST v1.1, CR is defined as disappearance of all target lesions. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression, taking as reference the smallest sum on study. Disease progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including baseline, or the appearance of one or more new lesions.
Time frame: From randomization until disease progression, up to 5 years
Time to Treatment Response
Calculated as the time from randomization to the first Occurrence of a documented Objective Response (CR or PR) determined according to RECIST 1.1. CR is defined as disappearance of all target lesions. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.
Time frame: From randomization until disease progression or death from any cause, up to 5 years
Duration of Response
Defined as the time from the first assessment of CR or PR until disease progression or death from any cause, whichever occurs first. CR is defined as disappearance of all target lesions. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.
Time frame: From first objective response until disease progression or death from any cause, up to 5 years
Percentage of Participants With Improvement and/or Stayed the Same on the Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score
Time frame: From baseline until end of study (up to 5 years)
| Milestone | Cohort 1: Induction Phase (IP) | Cohort 1 (Maintenance Phase[MP]):5-FU/LV,Cetuximab,Vemurafenib | Cohort 1 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab | Cohort 2 (IP) | Cohort 2 (MP):5-FU/LV or Capecitabine,Bevacizumab,Atezolizumab | Cohort 2 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab | Cohort 3 (IP) | Cohort 3 (MP): Capecitabine,Trastuzumab,Pertuzumab | Cohort 3 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab | Cohort 4 (IP) | Cohort 4 (MP): Cobimetinib,Atezolizumab | Cohort 4 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab | Early Progressing BRAFmut Cohort |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 93 | 0 | 0 | 635 | 0 | 0 | 6 | 0 | 0 | 310 | 0 | 0 | 0 |
| Treated during induction phase | 93 | 0 | 0 | 632 | 0 | 0 | 6 | 0 | 0 | 309 | 0 | 0 | 0 |
| Completed | 63 | 0 | 0 | 460 | 0 | 0 | 5 | 0 | 0 | 135 | 0 | 0 | 0 |
| Not completed | 30 | 0 | 0 | 175 | 0 | 0 | 1 | 0 | 0 | 175 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 24 | 0 | 0 | 0 | 0 | 0 | 18 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Death | 25 | 0 | 0 | 111 | 0 | 0 | 1 | 0 | 0 | 82 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 12 | 0 | 0 | 0 | 0 | 0 | 9 | 0 | 0 | 0 |
| Withdrew: Non-compliance | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Reason not specified | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 7 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Missing | 4 | 0 | 0 | 14 | 0 | 0 | 0 | 0 | 0 | 54 | 0 | 0 | 0 |
| Milestone | Cohort 1: Induction Phase (IP) | Cohort 1 (Maintenance Phase[MP]):5-FU/LV,Cetuximab,Vemurafenib | Cohort 1 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab | Cohort 2 (IP) | Cohort 2 (MP):5-FU/LV or Capecitabine,Bevacizumab,Atezolizumab | Cohort 2 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab | Cohort 3 (IP) | Cohort 3 (MP): Capecitabine,Trastuzumab,Pertuzumab | Cohort 3 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab | Cohort 4 (IP) | Cohort 4 (MP): Cobimetinib,Atezolizumab | Cohort 4 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab | Early Progressing BRAFmut Cohort |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 40 | 20 | 0 | 297 | 148 | 0 | 3 | 2 | 0 | 65 | 34 | 0 |
| Treated during maintenance phase | 0 | 40 | 18 | 0 | 293 | 143 | 0 | 3 | 2 | 0 | 64 | 34 | 0 |
| Completed | 0 | 6 | 2 | 0 | 66 | 21 | 0 | 0 | 1 | 0 | 12 | 6 | 0 |
| Not completed | 0 | 34 | 18 | 0 | 231 | 127 | 0 | 3 | 1 | 0 | 53 | 28 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 15 | 12 | 0 | 0 | 0 | 0 | 2 | 3 | 0 |
| Withdrew: Death | 0 | 29 | 16 | 0 | 188 | 107 | 0 | 1 | 1 | 0 | 46 | 19 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 | 15 | 4 | 0 | 1 | 0 | 0 | 3 | 3 | 0 |
| Withdrew: Reason not specified | 0 | 0 | 0 | 0 | 7 | 2 | 0 | 1 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Physician decision | 0 | 2 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 0 |
| Withdrew: Not treated | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Study ended by sponsor | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Non-compliance | 0 | 1 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Cohort 1: Induction Phase (IP) | Cohort 1 (Maintenance Phase[MP]):5-FU/LV,Cetuximab,Vemurafenib | Cohort 1 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab | Cohort 2 (IP) | Cohort 2 (MP):5-FU/LV or Capecitabine,Bevacizumab,Atezolizumab | Cohort 2 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab | Cohort 3 (IP) | Cohort 3 (MP): Capecitabine,Trastuzumab,Pertuzumab | Cohort 3 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab | Cohort 4 (IP) | Cohort 4 (MP): Cobimetinib,Atezolizumab | Cohort 4 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab | Early Progressing BRAFmut Cohort |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
PFS is defined as the time from randomization to the first occurrence of disease progression according to RECIST v1.1, or death from any cause, whichever occurs first. Progressive disease (PD) for target lesion: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of \>/=5 mm. PD for non-target lesion: Unequivocal progression of existing non-target lesions.
| months | Cohort 1 (Maintenance Phase[MP]):5-FU/LV,Cetuximab,Vemurafenib | Cohort 1 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab | Cohort 2 (MP):5-FU/LV or Capecitabine,Bevacizumab,Atezolizumab | Cohort 2 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab | Cohort 3 (MP): Capecitabine,Trastuzumab,Pertuzumab | Cohort 3 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab | Cohort 4 (MP): Cobimetinib,Atezolizumab | Cohort 4 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab |
|---|---|---|---|---|---|---|---|---|
| Progression-Free Survival (PFS) | 9.99 (7.72 to 12.55) | 11.60 (3.58 to 15.67) | 7.13 (6.14 to 8.41) | 7.36 (5.82 to 8.94) | 4.44 (3.55 to 14.69) | 4.04 (4.04 to 5.39) | 3.75 (3.42 to 3.91) | 7.79 (3.98 to 9.46) |
OS is defined as the time from randomization into the MTP to time of death from any cause.
| months | Cohort 1 (Maintenance Phase[MP]):5-FU/LV,Cetuximab,Vemurafenib | Cohort 1 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab | Cohort 2 (MP):5-FU/LV or Capecitabine,Bevacizumab,Atezolizumab | Cohort 2 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab | Cohort 3 (MP): Capecitabine,Trastuzumab,Pertuzumab | Cohort 3 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab | Cohort 4 (MP): Cobimetinib,Atezolizumab | Cohort 4 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab |
|---|---|---|---|---|---|---|---|---|
| Overall Survival (OS) | 24.02 (16.07 to 34.00) | 21.73 (7.92 to 37.19) | 22.54 (20.04 to 26.87) | 22.24 (18.50 to 25.13) | NA (NA to 16.07) | 14.59 (NA to NA) | 22.60 (14.23 to 27.40) | 25.17 (15.90 to 32.59) |
| percentage of participants | Cohort 1: Induction Phase (IP) | Cohort 1 (Maintenance Phase[MP]):5-FU/LV,Cetuximab,Vemurafenib | Cohort 1 Control: 5-FU/LV or Capecitabin, Bevacizumab | Cohort 2 (IP) | Cohort 2 (MP):5-FU/LV or Capecitabine,Bevacizumab,Atezolizumab | Cohort 2 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab | Cohort 3 (IP) | Cohort 3 (MP): Capecitabine,Trastuzumab,Pertuzumab | Cohort 3 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab | Cohort 4 (IP) | Cohort 4 (MP): Cobimetinib,Atezolizumab | Cohort 4 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab | Early Progressing BRAFmut Cohort |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Adverse Events | 98.9 | 100 | 94.4 | 96.0 | 95.6 | 88.1 | 100 | 100 | 100 | 97.4 | 98.4 | 88.2 | 90.9 |
Calculated as the number of participants with a best overall response of CR or PR according to RECIST 1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. OR= CR + PR.
| Participants | Cohort 1 (Maintenance Phase[MP]):5-FU/LV,Cetuximab,Vemurafenib | Cohort 1 Control(MP): 5-FU/LV or Capecitabin, Bevacizumab | Cohort 2 (MP):5-FU/LV or Capecitabine,Bevacizumab,Atezolizumab | Cohort 2 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab | Cohort 3 (MP): Capecitabine,Trastuzumab,Pertuzumab | Cohort 3 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab | Cohort 4 (MP): Cobimetinib,Atezolizumab | Cohort 4 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab |
|---|---|---|---|---|---|---|---|---|
| Overall Response | 20 | 5 | 49 | 22 | 1 | 0 | 7 | 8 |
DCR is defined as the percentage of participants with CR, PR, or stable disease (SD) at 16 weeks. Per RECIST v1.1, CR is defined as disappearance of all target lesions. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression, taking as reference the smallest sum on study. Disease progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including baseline, or the appearance of one or more new lesions.
| Participants | Cohort 1 (Maintenance Phase[MP]):5-FU/LV,Cetuximab,Vemurafenib | Cohort 1 Control(MP): 5-FU/LV or Capecitabin, Bevacizumab | Cohort 2 (MP):5-FU/LV or Capecitabine,Bevacizumab,Atezolizumab | Cohort 2 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab | Cohort 3 (MP): Capecitabine,Trastuzumab,Pertuzumab | Cohort 3 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab | Cohort 4 (MP): Cobimetinib,Atezolizumab | Cohort 4 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab |
|---|---|---|---|---|---|---|---|---|
| Disease Control Rate (DCR) | 36 | 15 | 227 | 111 | 1 | 0 | 44 | 26 |
Calculated as the time from randomization to the first Occurrence of a documented Objective Response (CR or PR) determined according to RECIST 1.1. CR is defined as disappearance of all target lesions. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.
| months | Cohort 1 (Maintenance Phase[MP]):5-FU/LV,Cetuximab,Vemurafenib | Cohort 1 Control(MP):5-FU/LV or Capecitabin, Bevacizumab | Cohort 2 (MP):5-FU/LV or Capecitabine,Bevacizumab,Atezolizumab | Cohort 2 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab | Cohort 3 (MP): Capecitabine,Trastuzumab,Pertuzumab | Cohort 3 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab | Cohort 4 (MP): Cobimetinib,Atezolizumab | Cohort 4 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab |
|---|---|---|---|---|---|---|---|---|
| Time to Treatment Response | 3.943 (1.18 to 29.70) | 5.552 (1.38 to 8.02) | 5.224 (1.22 to 26.74) | 4.616 (1.25 to 19.91) | 5.490 (5.490 to 5.490) | 0 (0 to 0) | 3.745 (1.77 to 14.92) | 2.530 (1.64 to 11.83) |
Defined as the time from the first assessment of CR or PR until disease progression or death from any cause, whichever occurs first. CR is defined as disappearance of all target lesions. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.
| months | Cohort 1 (Maintenance Phase[MP]):5-FU/LV,Cetuximab,Vemurafenib | Cohort 1 Control(MP):5-FU/LV or Capecitabin, Bevacizumab | Cohort 2 (MP):5-FU/LV or Capecitabine,Bevacizumab,Atezolizumab | Cohort 2 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab | Cohort 3 (MP): Capecitabine,Trastuzumab,Pertuzumab | Cohort 3 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab | Cohort 4 (MP): Cobimetinib,Atezolizumab | Cohort 4 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab |
|---|---|---|---|---|---|---|---|---|
| Duration of Response | 11.50 (7.66 to 21.49) | 8.74 (5.36 to 19.02) | 9.30 (5.55 to 11.30) | 7.59 (6.93 to 13.90) | 9.205 (9.205 to 9.205) | 0 (0 to 0) | 7.11 (1.48 to NA) | 6.06 (2.20 to 7.33) |
| percentage of participants | Cohort 1 (Maintenance Phase[MP]):5-FU/LV,Cetuximab,Vemurafenib | Cohort 1 Control(MP):5-FU/LV or Capecitabin, Bevacizumab | Cohort 2 (MP):5-FU/LV or Capecitabine,Bevacizumab,Atezolizumab | Cohort 2 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab | Cohort 3 (MP): Capecitabine,Trastuzumab,Pertuzumab | Cohort 3 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab | Cohort 4 (MP): Cobimetinib,Atezolizumab | Cohort 4 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab |
|---|---|---|---|---|---|---|---|---|
| Improved | 10.0 | 5.0 | 10.4 | 5.4 | 0 | 0 | 7.7 | 5.9 |
| Improved or stayed the same | 75.0 | 85.0 | 76.7 | 82.5 | 100 | 100 | 63.1 | 79.4 |
Collected over From baseline until end of study (up to 5 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: Induction Phase (IP) | 25/93 (26.9%) | 44/93 (47.3%) | 91/93 (97.8%) |
| Cohort 1 (Maintenance Phase[MP]):5-FU/LV,Cetuximab,Vemurafenib | 29/40 (72.5%) | 15/40 (37.5%) | 40/40 (100%) |
| Cohort 1 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab | 16/20 (80%) | 5/18 (27.8%) | 17/18 (94.4%) |
| Cohort 2 (IP) | 111/635 (17.5%) | 232/632 (36.7%) | 608/632 (96.2%) |
| Cohort 2 (MP):5-FU/LV or Capecitabine,Bevacizumab,Atezolizumab | 188/297 (63.3%) | 76/293 (25.9%) | 270/293 (92.2%) |
| Cohort 2 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab | 107/148 (72.3%) | 20/143 (14%) | 120/143 (83.9%) |
| Cohort 3 (IP) | 1/6 (16.7%) | 1/6 (16.7%) | 6/6 (100%) |
| Cohort 3 (MP): Capecitabine,Trastuzumab,Pertuzumab | 1/3 (33.3%) | 0/3 (0%) | 3/3 (100%) |
| Cohort 3 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab | 1/2 (50%) | 0/2 (0%) | 2/2 (100%) |
| Cohort 4 (IP) | 82/310 (26.5%) | 93/309 (30.1%) | 298/309 (96.4%) |
| Cohort 4 (MP): Cobimetinib,Atezolizumab | 46/65 (70.8%) | 26/64 (40.6%) | 61/64 (95.3%) |
| Cohort 4 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab | 19/34 (55.9%) | 3/34 (8.8%) | 29/34 (85.3%) |
| Early Progressing BRAFmut Cohort | 10/11 (90.9%) | 3/11 (27.3%) | 11/11 (100%) |
| Event | Cohort 1: Induction Phase (IP) | Cohort 1 (Maintenance Phase[MP]):5-FU/LV,Cetuximab,Vemurafenib | Cohort 1 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab | Cohort 2 (IP) | Cohort 2 (MP):5-FU/LV or Capecitabine,Bevacizumab,Atezolizumab | Cohort 2 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab | Cohort 3 (IP) | Cohort 3 (MP): Capecitabine,Trastuzumab,Pertuzumab | Cohort 3 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab | Cohort 4 (IP) | Cohort 4 (MP): Cobimetinib,Atezolizumab | Cohort 4 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab | Early Progressing BRAFmut Cohort |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Colonic fistulaGastrointestinal disorders | 0/93 | 0/40 | 0/18 | 0/632 | 0/293 | 0/143 | 1/6 | 0/3 | 0/2 | 0/309 | 0/64 | 0/34 | 0/11 |
| Abdominal painGastrointestinal disorders | 2/93 | 1/40 | 0/18 | 4/632 | 1/293 | 1/143 | 0/6 | 0/3 | 0/2 | 6/309 | 1/64 | 0/34 | 1/11 |
| DiarrhoeaGastrointestinal disorders | 5/93 | 1/40 | 1/18 | 13/632 | 5/293 | 2/143 | 0/6 | 0/3 | 0/2 | 4/309 | 2/64 | 0/34 | 1/11 |
| GastroenteritisInfections and infestations | 1/93 | 0/40 | 0/18 | 3/632 | 2/293 | 0/143 | 0/6 | 0/3 | 0/2 | 0/309 | 0/64 | 0/34 | 1/11 |
| DehydrationMetabolism and nutrition disorders | 3/93 | 0/40 | 0/18 | 3/632 | 0/293 | 0/143 | 0/6 | 0/3 | 0/2 | 3/309 | 1/64 | 0/34 | 1/11 |
| IleusGastrointestinal disorders | 2/93 | 1/40 | 1/18 | 10/632 | 2/293 | 0/143 | 0/6 | 0/3 | 0/2 | 2/309 | 0/64 | 0/34 | 0/11 |
| Implant site thrombosisGeneral disorders | 1/93 | 0/40 | 1/18 | 0/632 | 0/293 | 0/143 | 0/6 | 0/3 | 0/2 | 0/309 | 0/64 | 0/34 | 0/11 |
| CholestasisHepatobiliary disorders | 2/93 | 0/40 | 1/18 | 0/632 | 0/293 | 0/143 | 0/6 | 0/3 | 0/2 | 0/309 | 0/64 | 0/34 | 0/11 |
| Abdominal wall abscessInfections and infestations | 2/93 | 0/40 | 1/18 | 0/632 | 0/293 | 0/143 | 0/6 | 0/3 | 0/2 | 0/309 | 0/64 | 0/34 | 0/11 |
| Device related infectionInfections and infestations | 2/93 | 0/40 | 1/18 | 2/632 | 1/293 | 0/143 | 0/6 | 0/3 | 0/2 | 0/309 | 0/64 | 0/34 | 0/11 |
| Event | Cohort 1: Induction Phase (IP) | Cohort 1 (Maintenance Phase[MP]):5-FU/LV,Cetuximab,Vemurafenib | Cohort 1 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab | Cohort 2 (IP) | Cohort 2 (MP):5-FU/LV or Capecitabine,Bevacizumab,Atezolizumab | Cohort 2 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab | Cohort 3 (IP) | Cohort 3 (MP): Capecitabine,Trastuzumab,Pertuzumab | Cohort 3 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab | Cohort 4 (IP) | Cohort 4 (MP): Cobimetinib,Atezolizumab | Cohort 4 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab | Early Progressing BRAFmut Cohort |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EpistaxisRespiratory, thoracic and mediastinal disorders | 18/93 | 4/40 | 1/18 | 121/632 | 23/293 | 16/143 | 3/6 | 0/3 | 2/2 | 61/309 | 6/64 | 3/34 | 3/11 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 16/93 | 5/40 | 4/18 | 98/632 | 44/293 | 25/143 | 4/6 | 3/3 | 0/2 | 19/309 | 1/64 | 3/34 | 2/11 |
| DiarrhoeaGastrointestinal disorders | 52/93 | 16/40 | 4/18 | 282/632 | 78/293 | 21/143 | 4/6 | 2/3 | 0/2 | 134/309 | 40/64 | 8/34 | 5/11 |
| FatigueGeneral disorders | 31/93 | 9/40 | 2/18 | 247/632 | 52/293 | 23/143 | 4/6 | 1/3 | 0/2 | 87/309 | 12/64 | 7/34 | 3/11 |
| NauseaGastrointestinal disorders | 53/93 | 16/40 | 0/18 | 298/632 | 64/293 | 27/143 | 2/6 | 0/3 | 0/2 | 129/309 | 17/64 | 6/34 | 3/11 |
| ConstipationGastrointestinal disorders | 23/93 | 5/40 | 0/18 | 158/632 | 38/293 | 17/143 | 2/6 | 0/3 | 1/2 | 58/309 | 7/64 | 2/34 | 1/11 |
| Gingival bleedingGastrointestinal disorders | 2/93 | 2/40 | 0/18 | 9/632 | 5/293 | 0/143 | 1/6 | 0/3 | 1/2 | 0/309 | 0/64 | 0/34 | 0/11 |
| Mucosal inflammationGeneral disorders | 16/93 | 7/40 | 2/18 | 69/632 | 20/293 | 7/143 | 3/6 | 1/3 | 0/2 | 57/309 | 4/64 | 1/34 | 2/11 |
| Peripheral sensory neuropathyNervous system disorders | 26/93 | 4/40 | 1/18 | 222/632 | 32/293 | 15/143 | 3/6 | 0/3 | 0/2 | 58/309 | 3/64 | 4/34 | 0/11 |
| Skin exfoliationSkin and subcutaneous tissue disorders | 1/93 | 1/40 | 0/18 | 6/632 | 5/293 | 0/143 | 1/6 | 0/3 | 1/2 | 0/309 | 0/64 | 0/34 | 0/11 |
| Age, Continuous(years) | Cohort 1: Induction Phase (IP) | Cohort 2 (IP) | Cohort 3 (IP) | Cohort 4 (IP) | Total |
|---|---|---|---|---|---|
| Mean | 59.5 ± 12.0 | 60.9 ± 12.6 | 48.0 ± 7.7 | 60.1 ± 10.3 | 60.5 ± 11.9 |
| Age, Customized(Participants) | Cohort 1: Induction Phase (IP) | Cohort 2 (IP) | Cohort 3 (IP) | Cohort 4 (IP) | Total |
|---|---|---|---|---|---|
| In utero | 0 | 0 | 0 | 0 | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 0 | 0 | 0 | 0 | 0 |
| Children (2-11 years) | 0 | 0 | 0 | 0 | 0 |
| Adolescents (12-17 years) | 0 | 0 | 0 | 0 | 0 |
| Adults (18-64 years) | 58 | 351 | 6 | 199 | 614 |
| From 65-84 years | 35 | 279 | 0 | 110 | 424 |
| 85 years and over | 0 | 5 | 0 | 1 | 6 |
| Sex: Female, Male(Participants) | Cohort 1: Induction Phase (IP) | Cohort 2 (IP) | Cohort 3 (IP) | Cohort 4 (IP) | Total |
|---|---|---|---|---|---|
| Female | 49 | 247 | 4 | 123 | 423 |
| Male | 44 | 388 | 2 | 187 | 621 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1: Induction Phase (IP) | Cohort 2 (IP) | Cohort 3 (IP) | Cohort 4 (IP) | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 5 | 52 | 1 | 49 | 107 |
| Not Hispanic or Latino | 75 | 494 | 4 | 247 | 820 |
| Unknown or Not Reported | 13 | 89 | 1 | 14 | 117 |
| Race (NIH/OMB)(Participants) | Cohort 1: Induction Phase (IP) | Cohort 2 (IP) | Cohort 3 (IP) | Cohort 4 (IP) | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 9 | 0 | 14 | 24 |
| Asian | 5 | 15 | 0 | 16 | 36 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 1 | 1 |
| Black or African American | 0 | 10 | 0 | 5 | 15 |
| White | 76 | 539 | 6 | 264 | 885 |
| More than one race | 0 | 0 | 0 | 1 | 1 |
| Unknown or Not Reported | 11 | 62 | 0 | 9 | 82 |
Showing the first 100 of 154 sites across 23 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2015 to primary completion in May 2019, 49 months.
Results were first posted in Jul 2020, 1 year 1 month after primary completion.
Of 120 industry-sponsored phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 72. This study's 49 months is above that.
Counting every sponsor, half of 618 studies reached it within 49 months; a quarter within 31 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cetuximab · Fluoropyrimidine · Atezolizumab · Vemurafenib · Bevacizumab · Trastuzumab · Pertuzumab · Cobimetinib · Capecitabine